Xenetic Biosciences, Inc.
(NASDAQ : XBIO)

( )
XBIO PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.65%190.201.2%$530.70m
TSROTESARO, Inc.
0.23%73.9514.4%$516.06m
CELGCelgene Corporation
-0.90%69.451.2%$506.39m
GILDGilead Sciences, Inc.
1.22%68.980.9%$497.89m
ILMNIllumina, Inc.
-3.86%321.413.5%$363.96m
BIIBBiogen Inc.
-3.05%316.731.3%$352.14m
REGNRegeneron Pharmaceuticals, Inc.
-2.32%372.832.6%$248.08m
VRTXVertex Pharmaceuticals Incorporated
-4.12%172.211.9%$245.33m
AAgilent Technologies, Inc.
-2.34%70.231.5%$233.08m
ALXNAlexion Pharmaceuticals, Inc.
-4.49%115.602.0%$139.06m
SRPTSarepta Therapeutics, Inc.
-3.35%121.3815.4%$129.29m
NKTRNektar Therapeutics
-2.76%36.995.5%$106.49m
EXASExact Sciences Corporation
-4.30%71.7025.3%$105.84m
INCYIncyte Corporation
-0.91%64.512.5%$103.69m
EXELExelixis, Inc.
-2.65%20.546.4%$81.16m

Company Profile

Xenetic Biosciences, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, research, and development of next generation biologic drugs and novel orphan oncology therapeutics. Its lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod), which focuses on the treatment of progesterone resistant endometrial cancer. It also offers proprietary drug development platform, PolyXen, which enables next-generation biologic drugs by improving their half-life and other pharmacological properties. The company was founded on August 9, 2011 and is headquartered in Lexington, MA.